Business
CEO Review and Update
CEO Review and Update.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9005T Cambridge Cognition Holdings PLC 26 November 2013 \n \n\n\nCambridge Cognition Holdings Plc \n('Cambridge Cognition' or the 'Company')\n \nCEO Review and Update\n \nCambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, provides a review of strategy and update on trading, following the completion of Nick Kerton's first three months as Chief Executive Officer:\n \n\"As I reported at our Interim Results, the first six months of the financial year was very much about building a platform for future growth. In the three months since taking the role of Chief Executive, I have worked hard to clearly identify the opportunities and challenges that our business faces. I am pleased to say that I remain confident about the overall outlook of the business. Cambridge Cognition, more so than ever, has a strategic focus and is developing a fully functioning commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales.\n \nMeanwhile, we have developed the requisite commercial infrastructure to deliver future growth. We have established a new commercial sales office in Chicago with four full time employees, which includes a Chief Commercial Officer, overseeing the commercialisation of our products and developing targeted line extensions. We expect to recruit a new Business Development Manager to complement our existing Pharmaceutical sales in the UK, and who will develop a pharmaceutical product portfolio for new areas of application, extending the range of clinical trials that we can target. We have also introduced a new customer services team to provide strong support to our commercial activities, as well as driving strong sales activities to boost the Academic business. Furthermore, we have seen an increase in enquiries from potential customers wishing to work with Cambridge Cognition for an OEM offering based on our CANTABTM technology. \n \nHaving reduced our annual cost base by £1.4m, we believe it is now correctly aligned with trading conditions within our core Pharmaceutical business, as well as our modest but growing position in the primary healthcare markets with our CE-marked Class II medic...